BBIO BridgeBio Pharma Inc
Price (delayed)
$34.62
Market cap
$6.58B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.88
Enterprise value
$8.11B
BridgeBio Pharma Inc. is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in
Highlights
BridgeBio Pharma's quick ratio has soared by 52% from the previous quarter and by 41% YoY
BridgeBio Pharma's gross margin has increased by 33% YoY
BBIO's EPS is up by 27% year-on-year but it is down by 20% since the previous quarter
BBIO's net income is down by 22% since the previous quarter but it is up by 17% year-on-year
BBIO's debt is up by 28% since the previous quarter and by 27% year-on-year
BBIO's equity is down by 19% since the previous quarter and by 8% year-on-year
Key stats
What are the main financial stats of BBIO
Market
Valuations
Earnings
Shares outstanding
190.19M
Market cap
$6.58B
Enterprise value
$8.11B
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
29.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
36.56
Revenue
$221.9M
Gross profit
$218.02M
Operating income
-$592.97M
Net income
-$535.76M
EBIT
-$435.32M
EBITDA
-$425.13M
Free cash flow
-$521.66M
Per share
Balance sheet
Liquidity
EPS
-$2.88
EPS diluted
-$2.88
Free cash flow per share
-$2.8
Book value per share
-$7.77
Revenue per share
$1.19
TBVPS
$4.81
Total assets
$919.34M
Total liabilities
$2.38B
Debt
$2.21B
Equity
-$1.47B
Working capital
$566.29M
Debt to equity
-1.51
Current ratio
4.67
Quick ratio
4.44
Net debt/EBITDA
-3.6
Margins
Efficiency
Dividend
EBITDA margin
-191.6%
Gross margin
98.3%
Net margin
-241.4%
Operating margin
-267.2%
Return on assets
-66.4%
Return on equity
N/A
Return on invested capital
-22.2%
Return on capital employed
-56.9%
Return on sales
-196.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BBIO stock price
How has the BridgeBio Pharma stock price performed over time
Intraday
4.85%
1 week
-4.1%
1 month
-0.8%
1 year
20.21%
YTD
26.17%
QTD
0.14%
Financial performance
How have BridgeBio Pharma's revenue and profit performed over time
Revenue
$221.9M
Gross profit
$218.02M
Operating income
-$592.97M
Net income
-$535.76M
Gross margin
98.3%
Net margin
-241.4%
BBIO's net margin has surged by 97% year-on-year but it is down by 20% since the previous quarter
BBIO's operating margin has soared by 96% YoY but it is down by 9% QoQ
BridgeBio Pharma's gross margin has increased by 33% YoY
BBIO's net income is down by 22% since the previous quarter but it is up by 17% year-on-year
Growth
What is BridgeBio Pharma's growth rate over time
Valuation
What is BridgeBio Pharma stock price valuation
P/E
N/A
P/B
N/A
P/S
29.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
36.56
BBIO's EPS is up by 27% year-on-year but it is down by 20% since the previous quarter
BBIO's equity is down by 19% since the previous quarter and by 8% year-on-year
The stock's price to sales (P/S) is 88% less than its 5-year quarterly average of 233.3 but 20% more than its last 4 quarters average of 23.0
Efficiency
How efficient is BridgeBio Pharma business performance
BBIO's ROS has soared by 97% year-on-year but it is down by 22% since the previous quarter
The ROA has grown by 40% YoY but it has contracted by 8% from the previous quarter
The ROIC has grown by 31% YoY but it has contracted by 16% from the previous quarter
Dividends
What is BBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BBIO.
Financial health
How did BridgeBio Pharma financials performed over time
BBIO's total assets is 61% smaller than its total liabilities
BBIO's total assets has soared by 68% year-on-year and by 38% since the previous quarter
BridgeBio Pharma's quick ratio has soared by 52% from the previous quarter and by 41% YoY
BBIO's debt is up by 28% since the previous quarter and by 27% year-on-year
BBIO's equity is down by 19% since the previous quarter and by 8% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.